The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases.
Kazuma YagiMakoto IshiiHo NamkoongTakahiro AsamiOsamu IketaniTakanori AsakuraShoji SuzukiHiroaki SugiuraYoshitake YamadaTomoyasu NishimuraHiroshi FujiwaraYohei FunatsuYoshifumi UwaminoTetsuro KamoSadatomo TasakaTomoko BetsuyakuNaoki HasegawaPublished in: BMC infectious diseases (2017)
Inhaled AMK therapy is an effective and feasible therapy for difficult-to-treat NTM lung disease.